Omnicell reported GAAP revenues of $229.7 million, a 13.4% increase from Q1 2019. GAAP net income was $11.3 million, or $0.26 per diluted share, compared to $3.3 million, or $0.08 per diluted share, in the first quarter of 2019. The company withdrew its previously issued full year 2020 financial guidance due to the uncertainty surrounding the COVID-19 pandemic.
GAAP and non-GAAP revenues of $229.7 million, up 13.4% year-over-year
GAAP net income per diluted share of $0.26, up 225.0% year-over-year
Non-GAAP net income per diluted share of $0.66, up 8.2% year-over-year
Launched a Rapid Response program to fast-track production and deployment of XT Series automated dispensing systems
As a result of the uncertainty surrounding the COVID-19 pandemic, the Company withdraws its previously issued full year 2020 financial guidance that was provided on February 6, 2020, and is unable to provide second quarter or full year 2020 guidance at this time.
Analyze how earnings announcements historically affect stock price performance